AcelRx Pharmaceuticals’ programs to feature at upcoming annual meeting

Download PDF Copy

Oct 15 2009

AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 1 studies evaluating the pharmacokinetics of its oral transmucosal NanoTab(TM) formulation of sufentanil will be featured in two oral presentations at the upcoming American Society of Anesthesiologists Annual Meeting in New Orleans.

Dr. Pamela Palmer, Chief Medical Officer of AcelRx, will present in the following sessions. Abstracts are available through the American Society of Anesthesiologists web site.

Tuesday, October 20, 2009 Oral Session - Chronic & Cancer Pain 8:00 am, Room 355 Abstract 1040 "Pharmacokinetics and Dose Proportionality of Sublingual Sufentanil NanoTab in Healthy Volunteers" Tuesday, October 20, 2009 Oral Session - Regional Anesthesia & Acute Pain 1:00 pm, Room 355 Abstract 1222 "Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers"

Source:

AcelRx Pharmaceuticals, Inc.

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

International commission calls for action against hepatocellular carcinoma

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

COPD care pathways improve hospital outcomes and standardize treatment

Targeting gut signaling protein may protect against alcohol-related liver damage

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Edible microbeads trap fat to support weight loss

WHO expands global network of trusted medical product regulators

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.